biotech / news / / Times Now
The US Food and Drug Administration has approved the first-ever gene therapy designed to treat genetic hearing loss.
The FDA has approved Otarmeni, the first-ever gene therapy for genetic hearing loss.
KEY POINTS
- Otarmeni targets OTOF gene mutations, affecting only about 50 babies born in the US annually.
- Regeneron will provide Otarmeni free of cost to eligible patients during its initial rollout phase.
- Clinical trials showed 16 out of 20 children had significant hearing improvement, including whisper detection.
COMPANIES
Summarized by Newsio from Times Now. How we summarize →